Rare variants are considered underlying causes of complex diseases. The complex and severe group of disorders called neural tube defects (NTDs) results from failure of the neural tube to close during early embryogenesis. Neural tube closure requires the coordination of numerous signaling pathways, including the precise regulation of retinoic acid (RA) concentration, which is controlled by enzymes involved in RA synthesis and degradation. Here, we used a case-control mutation screen study to reveal rare variants in retinoid-related genes in a Han Chinese NTD population by sequencing six genes in 355 NTD cases and 225 controls. More specific rare variants were found in exonic and upstream regions in NTD cases. The RA-responsive genes CYP26A1, CRABP1, and ALDH1A2 harbored NTD-specific rare variants in their upstream regions. Unexpectedly, the majority of missense variants in NTD cases were found in CYP26B1, which encodes a RA degradation enzyme, whereas no missense variants in this gene were found in controls. Functional analysis indicated that the CYP26B1 NTD variants were inefficient in the degradation of RA using assays of RA-induced transcription and RA-initiated neuronal differentiation. Our study supports the contribution of rare variants in RA-related genes to the etiology of human NTDs.
INTRODUCTION
Rare variants are causal genetic factors for complex diseases (Bruel et al., 2017; Manolio et al., 2009) . Neural tube defects (NTDs; MIM# 601634) are complex congenital malformations of the central nervous system, caused by failure of neural tube closure during embryogenesis.
NTDs include cranial defects such as anencephaly and encephalocele and caudal defects including spina bifida. Genetic studies of mice have identified more than 240 genes involved in neural tube closure (Harris & Juriloff, 2010; Wilde, Petersen, & Niswander, 2014; Wilson, & Maden, 2005) and this information has provided a framework to explore the genetic causes of NTDs in humans over the past decade (Chen et al., 2017; De Marco et al., 2014; Kibar et al., 2007; Qiao et al., 2016) . Genes that function in particular pathways involved in planar cell polarity (PCP), ciliogenesis, the glycine cleavage system and one-carbon metabolism have been explored in a relatively large number of cases (Allache et al., 2015; Cai & Shi, 2014; De Marco et al., 2014; Dowdle et al., 2011; Hopp et al., 2011; Jones, Fiozzo, Waters, McKnight, & Brown, 2014; Kibar et al., 2007; Lei et al., 2013; Lei et al., 2014; Lei et al., 2010; Marini et al., 2011; Merello et al., 2015; Miao et al., 2016; Narisawa et al., 2012; Qiao et al., 2016; Roberson et al., 2015; Robinson et al., 2012; Shaheen et al., 2015; Yang et al., 2013; Zhang et al., 2015) . PCP gene variants have been associated with the most severe NTD phenotype, craniorachischisis, as well as more limited NTDs such as myelomeningocele. Rare variants in cilia genes have been associated with human cranial NTD phenotypes (Chen et al., 2017; Miao et al., 2016) and multiple potentially damaging mutations in cilia genes and the TMEM superfamily were found in MeckelGruber syndrome patients, a prenatal lethal disorder characterized by the traits of occipital encephalocele, polydactyly, and polycystic kidney (Dowdle et al., 2011; Hopp et al., 2011; Jones et al., 2014; Roberson et al., 2015; Shaheen et al., 2015; Zhang et al., 2015) . Several NTD-specific missense mutations and splicing variants were identified in genes that function in the glycine cleavage system and one-carbon metabolism (Marini et al., 2011; Narisawa et al., 2012; Saxena, Gupta, Pandey, Gangopadhaya, & Pandey, 2011; Tilley, Northrup, & Au, 2012) .
These pathways have been relatively well explored for their association with NTDs in human, but many NTD cases have no known genetic etiology.
The vitamin A derivative retinoic acid (RA) is essential for the patterning and differentiation of neural progenitor cells in the hindbrain and spinal cord (Duester, 2008; Guan, Chang, Rolletschek, & Wobus, 2001; Maden, 2007) . It is critical to maintain an appropriate balance of the essential vitamin A and RA, as too much or too little is associated with a range of birth defects (Alles, & Sulik, 1990; Chen, Morriss-Kay, & Copp, 1995; Iulianella, Beckett, Petkovich, & Lohnes, 1999; Lee et al., 2012; Maden, Gale, Kostetskii, & Zile, 1996) . During embryogenesis, levels of RA are established by the synthesizing enzyme ALDH1A2 and the degradative enzymes CYP26A1/CYP26B1/CYP26C1 ( Figure 1A ) (Niederreither et al., 2002; Pennimpede et al., 2010) .
Moreover, RA signaling is exquisitely controlled locally and this is accomplished by the tissue-specific expression of retinoid metabolism genes to allow localized production and destruction of RA. RA acts as a ligand and associates with two families of nuclear receptors that bind DNA through RA response elements (RARE) and directly regulate transcription. RA receptors (RARA, RARB, and RARG) bind the abundant form of RA known as all-trans-RA and the retinoid X receptors (RXRA, RXRB, and RXRG) bind an isomer known as 9-cis-RA (Chawla, Repa, Evans, & Mangelsdorf, 2001) .
The relationship between genetic polymorphisms in retinoid metabolism genes and increased risk of NTDs in humans is well documented. A polymorphism discovery screen was carried out for ALDH1A2 (MIM# 603687), CYP26A1 (MIM# 602239), CYP26B1 (MIM# 605207), CRABP1 (MIM# 180230), and CRABP2 (MIM# 180231) genes in 230 individuals with lumbosacral myelomeningocele (including spina bifida aperta or spina bifida cystica), and a significant association between three polymorphisms in ALDH1A2 and this spinal NTD was identified (Deak et al., 2005) . In another study, a deletion (g.3116delT) in the CYP26A1 gene, which creates a premature stop codon, was found in a sample of 40 spina bifida patients of Caucasian origin from southern Italy (Rat et al., 2006) . Moreover, investigation of the three RA receptors encoded by RARA (MIM# 180240), RARB (MIM# 180220), and RARG (MIM# 180190) in 329 affected family trios and 281 affected family duos of patients with meningomyelocele from Texas, identified SNPs in each of these genes and these were associated with a protective effect against meningomyelocele (Tran et al., 2011) . It is important to test the functional significance of rare variants to begin to develop a deeper mechanistic understanding of NTDs in humans.
This has been done for some of the studies above, such as testing how PCP variants affect cell behavior or how truncated CYP26A1 affects RA metabolism (Rat et al., 2006) .
To increase our knowledge as to the importance of RA-related genes in a broader range of NTDs in human, we analyzed a Han Chinese population that included 355 NTD cases ranging from cranial to caudal defects and 225 ethnicity-matched controls. We focused on genes in six RA metabolism and signaling-related genes (underlined in Figure 1A ). This case-control mutation screen showed a strong correlation between rare variants in RA-related genes in cranial and caudal NTDs. Strikingly, CYP26B1 harbored numerous missense variants within the gene body. We also provide experimental evidence that these CYP26B1 variants disrupt function as assessed by the transcription of RA target genes and RA-mediated differentiation of neuroepithelial cells.
SUBJECTS AND METHODS

Subjects
As described in our previous article , we performed high-throughput sequencing of genomic DNA samples collected from subjects with NTD in the Han Chinese population ranging in age from gestational week (GW) 12 to 10 years old and from multiple local hospitals in six provinces in China. Ethnicity-matched controls were collected from non-medically related terminations and were free of any NTDs. We enrolled individuals with NTDs that had been assessed by clinical geneticists and placed them into at least one of the following diagnostic groups: anencephaly, spina bifida (aperta, occulta or cystica), craniorachischisis, and encephalocele. In total, there were 19 individuals with craniorachischisis; 17 anencephaly; 55 anencephaly with spina bifida aperta; two anencephaly with spina bifida cystica; 27 encephalocele and spina bifida aperta; 57 encephalocele; 91 spina bifida aperta; 26 spina bifida occulta; 42 spina bifida cystica; and 19 spina bifida without further clinical details. 
Genomic DNA sequencing
Similar to our previous article (Li, & Durbin, 2009 short indels (insertions and deletion) were called using Varscan with a loose standard (minimum coverage = 2, minimum alternative allele reads = 2, minimum variation frequency > 0.1). Genotypes were called using Bayes. Variants were annotated with ANNOVAR (Wang, Li, & Hakonarson, 2010) . Rare variants were filtered out using the dbSNP in NCBI, the 1000 Genomes Project, the NHLBI Exome Sequencing Project, and shared variants in cases and controls. 
Neuroepithelial cell line and plasmid transfection
Western blotting
Proteins extracts were subjected to polyacrylamide gel electrophoresis and electrotransfer to PVDF membranes. The membranes were blocked with 5% non-fat milk and then probed with the indicated antibodies in TBS-Tween, Antibodies used were against 2H8 antiturboGFP (Origene; TA150041, 1:2,000), anti-turboRFP clone OTI2D9
(Origene; TA150061, 1:1,000), anti-Gapdh (Sigma; G9545, 1:2,000),
anti-RARA(c-20) (Santa Cruz, Dallas, USA; sc-551, 1:50), anti-RARB(C-19) (Santa Cruz; sc-552, 1:50), anti-RARG(C-19) (Santa Cruz; sc-550;
1:50), and -tubulin (Sigma; T3952, 1:2,000). 
Immunofluorescence staining
Real-time quantitative PCR
RNA was isolated according to manufacturer's instructions using the High Pure RNA Isolation Kit (Roche, Indianapolis, USA) and cDNA was generated using random hexamers and the Transcriptor First Strand 18 cDNA Synthesis Kit (Roche). qPCR was performed on a LightCycler 480 (Roche) using the LightCycler 480 Probes Master reagent (Roche) and Universal Probe Library (Roche) according to manufacturer's protocol. All primers and probes are listed in Supp. Table S1 .
Data were collected and analyzed with LightCycler 480 Software (Roche; Version 1.5.1). All experiments were from three biological replicates.
Statistical analysis
For genetic variation analyses, Fisher's exact test was used to compare the difference between cases and controls and false discovery rate (FDR) correction was performed (Benjamini, Drai, Elmer, Kafkafi, & Golani, 2001 ). The Student's t-test was used for Western blot and immunofluorescent staining experiments (*P < 0.05, **P < 0.01, ***P < 0.0001).
RESULTS
Retinoid-related genes harbor disease-specific rare variants in exonic and upstream regions in NTD cases
Vitamin A is processed by the retinoid metabolism pathway to RA ( Figure 1A ) and signaling through this pathway is critical for neural patterning, neural differentiation, and neural tube closure (Copp, & Greene, 2010; Duester, 2008; Maden, 2007) . We performed a case-control mutation screen by sequencing the RA pathway genes ALDH1A2, CRABP1, CRABP2, RARA, CYP26A1, and CYP26B1 in 355 NTD cases affecting cranial or caudal central nervous system and 225 controls from the Han Chinese population.
For these six genes in control and NTD cases, we found 1,002 variants in total. NTD-specific rare variants were slightly more than control-specific rare variants ( Figure 1B ; P = 0.0654; Q = 0.1177).
Although there was no significant difference between NTD cases and controls for rare variants present in intronic, 5 ′ UTR or 3 ′ UTR regions, the number of NTD-specific rare variants increased significantly within Tables 1 and 2. For the rare variants identified in upstream regions, defined as 2,000 bp upstream of transcription start site, the majority were found in CYP26A1, CRABP1, and ALDH1A2. In the upstream regions, we found six occurrences of two NTD-specific rare variants in CYP26A1, four occurrences of three rare variants in CRABP1 and six occurrences of six rare variants in ALDH1A2 (Table 2 and Figure 1D 2). In cDNA change, nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.
impact their transcriptional regulation by RA, an idea that remains to be tested. Additionally, using PROMO (Farre et al., 2003; Messeguer et al., 2002) to predict transcription factor binding sites in the human genome, these variants could disrupt binding ( Figure 1D -F), highlighting the possible functional importance of these variants in the regulation of gene expression. Furthermore, we found a deletion in CYP26A1
(CYP26A1:NC_000010.10:g.94832265_94832266del) occurred four times ( Figure 1D ) and a total of three recurrent rare mutations were found in the upstream regions of CYP26A1 and CRABP1 ( Figure 1D and E), thus emphasizing the possible association of these variants with NTD prevalence. All variants reported were submitted to the ClinVar (Submission ID: SUB3259094; https://submit.ncbi.nlm.nih.gov/ subs/clinvar_file/SUB3259094/overview).
We next correlated exonic or upstream variants with the clinical phenotype. The 18 occurrences of NTD-specific rare variants in exonic regions were present in the following cases: nine spina bifida, four encephalocele, two craniorachischisis, two spina bifida with encephalocele, and one anencephaly ( Table 1 ). The 21 occurrences in upstream regions were present in twelve spina bifida, five anencephaly with spina bifida, two encephalocele, one encephalocele with spina bifida, and one anencephaly (Table 2 ). Thus, rare variants in retinoid metabolism genes can be associated with multiple types of NTDs (Tables 1 and 2 ). Interestingly, some cases who carry missense variants in CYP26B1 and/or variants in upstream regions of CYP26A1, RARA, ALDH1A2, and CRABP2 exhibit pulmonary hypoplasia or urinary malformation or limb malformation (Tables 1 and 2) , consistent with the phenotypes seen in mice with genetic-deficiencies of these genes (Chen et al., 2010; Lee et al., 2012; Maclean, Dolle, & Petkovich, 2009; Malpel, Mendelsohn, & Cardoso, 2000) , emphasizing the importance of RA for neural tube, lung, urinary system, and limb development.
In total, 158 common variants were found in the present study.
Following Hardy-Weinberg equilibrium modeling in control and filtering, four SNPs were associated with risk of human NTDs (Supp. Table S2 ). Amongst them, CRABP2 rs12039622:T > C and CYP26B1 rs917896:C > T appear as risk factors for the disease, whereas ALDH1A2 rs4646579:G > C and rs4238328:G > A may play protective roles (Supp . Table S2 ).
RA degradation enzyme CYP26B1 gene harbors the most NTD-specific missense rare variants
We found the CYP26B1 gene harbored the most NTD-specific rare variants within the exonic regions of the six genes analyzed (Table 3; 12 exonic variants in CYP26B1 vs. six for the remaining five genes) and more than the single CYP26B1 exonic variant identified in controls (Table 3 ; P = 0.0215, Q = 0.129 after FDR correction). Moreover, nine of the 12 exonic variants in the CYP26B1 gene in NTD cases were missense or predicted splicing mutations, significantly more than in control (Table 1 ; NTD vs. Control: 9/355 vs. 0/225; P = 0.0152). The two ALDH1A2 and one CRABP1 exonic variants were also missense or predicted splicing mutations, whereas the three CYP26A1 exonic variants were silent mutations ( Table 1) .
The CYP26B1 gene is located on chromosome 2 in the p13.2 genomic region ( Figure 2A ). According to the database from Exome Aggregation Consortium (ExAC), this gene is intolerant for missense mutations (z = 2.06) and extremely intolerant for loss-of-function mutations (pLI = 0.95) (Supp . Table S3 ) (Lek et al., 2016) . In our case-control study, the coding and non-coding regions of the gene were examined. In total, there were 45 occurrences of NTD-specific and 16 occurrences of control-specific rare variants in the CYP26B1 TA B L E 3 Summary of rare variants harbored in exonic regions and upstream regions of sequenced genes involved in retinoid-related metabolism and signaling around two substrate-recognition sites ( Figure 2C ). Sanger sequencing was performed to confirm the rare variants ( Figure 2D and not shown). Three NTD-specific variants would be expected to yield silent mutations (NP_063938.1:p.Arg77 = , p.Leu169 = and p.Leu322 = ), four to yield missense mutations (observed as eight occurrences: NP_063938.1:p.Arg195Trp, p.Leu197Met, p.Gln238Glu and p.Ala239Thr), and one splicing/exonic mutation (NC_000002.11:
In exonic
g.72362274C > T NP_063938.1:p.Arg235Gln). In contrast, only one silent mutation was found in control (NP_063938.1:p.Arg195 = , shown in green in Figure 2C ). Amongst them, the variants Figure 2E ). Notably, even when individuals carried the same missense mutation in CYP26B1, the clinical phenotypes varied and ranged from spinal to cranial defects ( Table 1 ), suggesting that these heterozygous missense mutations in CYP26B1 might contribute to the NTD but are not the unique determinant of the phenotype.
Predictions of the impact of rare variants on protein function
Rare missense or predicted splicing mutations have the potential to impact protein function and the studies above showed a significant burden of these potentially damaging NTD-specific variants in the CYP26B1 gene. Therefore we focused our attention on testing the impact of NTD-specific missense or splicing mutations in CYP26B1 gene. We first evaluated the predicted splicing/missense mutation NM_019885:c.704G > A, Arg235Gln, which occurred at the end of exon3 (Supp. Figure S1 ). Using Human Splice Finder 3.0 (Desmet et al., 2009 ), this variant is located in a splice donor site and could potentially influence splicing; moreover, it could create a new exonic splicing silencer (ESS) site. Furthermore, this variant in exon3 would be expected to create a missense mutation (p. (Arg235Gln)) (Supp. Figure S1B and S1C). This potential to alter both splicing and protein sequence lead us to evaluate the only other splicing mutation seen, which was in the ALDH1A2 gene. This occurred in exon10 (NM_003888) and the variant is predicted to create an exonic ESS site or an alteration of an exonic splicing enhancer (ESE), as well as to create a p.(Ile363Val) missense mutation. Therefore, we classified both of these as splicing/missense variants in Table 1 . We then evaluated the predicted effect of the individual missense variants on amino acid charge and hydrophobicity and used SIFT and Polyphen algorithms to predict the effect on protein function (Table 1 and Figure 2F ). These tools predict that all five missense variants tested below would impact protein function.
Functional analysis of CYP26B1 variants demonstrates loss-of-function in modulation of RA-mediated gene transcription
To experimentally test the impact of these predicted damaging mutations, we transiently expressed GFP-tagged WT CYP26B1 cDNA or mutant constructs containing each NTD specific-variant in a neuroepithelial cell line NE-4C and assessed protein expression, effect on RA-mediated transcription, and neural differentiation. The NE-4C neuroepithelial cell line is derived from embryonic day 9 mouse cranial neural tissue during the period of neural tube closure. Plasmids carrying WT or mutant CYP26B1 (all constructs fused to GFP) and an RFP-expression plasmid to control for transfection efficiency were transiently transfected into the NE-4C cells. The relative expression levels of GFP indicated that there were no significant difference between WT and mutant constructs (Supp. Figure S2A ). Western blot assays indicated that the protein level of RFP was similar for the WT and all mutant constructs and that the GFP antibody detected a prominent band at 84 kDa, the predicted size of the CYP26B1-GFP fusion protein for all constructs (CYP26B1 57 kDa plus GFP 27 kDa;
Supp. Figure S2B ). These constructs were used in NE-4C cells for the following functional studies.
RA can promote differentiation of neural stem cells and NE-4C cells Genes that were suppressed by WT CYP26B1 but not by the CYP26B1 variants were the direct RA targets Rarb and Crabp1 ( Figure 3A and B), which contain RARE sites and act in a feedback loop as components of the RA signaling pathway (Bastien, & Rochette-Egly, 2004; Wilde, Siegenthaler, Dent, & Niswander, 2017) ; Wnt11 ( Figure 3C ), which encodes a ligand for non-canonical Wnt signaling pathway (Hardy et al., 2008) ; Cdh2 encoding a cell adhesion protein ( Figure 3D) ; the transcription factor gene Foxa1 (Figure 3E ), which plays a role F I G U R E 3 CYP26B1 NTD-variants attenuate function as assessed by modulation of RA-mediated gene transcription. A-H: Real-time quantitative PCR assays were performed to test the mRNA levels of genes that are downstream of RA signaling and involved in neural development. NE-4C cells were transfected with CYP26B1 WT or mutant plasmids and treated for 24 hr with RA. Gapdh gene was used as a loading control. The level of expression is indicated as fold change relative to WT plasmid, which was set to 1. All experiments were from three biological replicates. ***P < 0.0001; **P < 0.01; *P < 0.05; Student's t-test in dorsal-ventral patterning of the neural tube (Maier, Lo, & Harfe, 2013) ; the homeobox gene Hoxb1 (Figure 3F ), which patterns progenitor cells in the hindbrain (Gaufo, Flodby, & Capecchi, 2000; Zigman, Laumann-Lipp, Titus, Postlethwait, & Moens, 2014) and consistent with the increase in Hoxb1 mRNA levels in RA-treated human neural stem cells (Colleoni et al., 2011) ; and Casp3 ( Figure 3G 
CYP26B1 variants impact modulation of neural differentiation
A well-known function of RA is to promote the differentiation of neural 
DISCUSSION
Our NTD case-control study has identified a significant number of rare mutations in retinoid metabolism genes associated with NTDs in humans. Furthermore, our functional experiments demonstrate that the NTD-specific missense mutations in CYP26B1 create lossof-function mutations. CYP26B1 acts to degrade RA and modulate RA signaling levels. Consistent with this, WT CYP26B1 decreases the expression of direct and indirect targets of RA signaling and inhibits RA-mediated neural differentiation. In contrast, the NTDspecific CYP26B1 variants show significantly attenuated function in these assays. These RA-mediated activities are relevant for the process of neural tube closure and hence we suggest that impairment in the balance of RA signaling due to CYP26B1 variants can contribute to NTD risk.
In our cohort, all variants found were genetically heterozygous, with the variant present on only one allele. From our sequencing data of six RA-related genes, CYP26B1 was most burdened of NTD-specific damaging mutations. All three CYP26 enzymes are dynamically Our functional experiments of the rare variants in the CYP26B1 gene found in our NTD cohort indicate they are partial or complete loss-of-function alleles. We postulate this leads to insufficient regulation of RA-mediated transcription and neural stem cell differentiation due to failure of RA degradation, which leads to supraphysiological RA accumulation. Excess RA can elicit NTDs in rat and mouse, ranging from caudal spina bifida aperta, to encephalocele and a combination of these NTDs (Alles, & Sulik, 1990; Cai et al., 2007) . In our present cohort, three of nine individuals carrying CYP26B1 missense rare variants displayed lower spina bifida, three individuals were affected with encephalocele, and one was affected with the combination of spina bifida and encephalocele: consistent with the rodent phenotypes.
Notably, two individuals exhibited craniorachischisis, highlighting the possibility that supraphysiological RA might be associated with a craniorachischisis phenotype, although there is no evidence that excess RA induces this phenotype in animal models. By contrast, lack of RA synthesis elicits craniorachischisis in mice (Niederreither, Subbarayan, Dolle, & Chambon, 1999) , emphasizing the importance of proper levels of RA in convergence and extension of the neural plate during early neural tube closure. It has been proposed that supraphysiological RA leads to spina bifida due to excessive cell death in the hindgut and mesenchyme ventral to the neuroepithelium of the posterior neuropore, and a disparity in growth between the ventral and dorsal regions of the tail bud causes the relatively faster growing dorsal region to evert, preventing closure of the caudal neural tube (Alles, & Sulik, 1990) . Our data show that the NTD-specific missense constructs cannot appropriately decrease the expression of Casp3 (Figure 3G ), consistent with the idea that apoptosis may be increased when levels of RA are in excess. Additionally, Hoxb1 is a crucial RA-responsive (Colleoni et al., 2011) regulator of hindbrain lumen morphogenesis (Zigman et al., 2014) and the NTD-specific mutant constructs are not capable of modulating Hoxb1 expression ( Figure 3F ) and this could contribute to possible CYP26B1 phenotypes.
Our human NTD sequencing data also identified a significant number of NTD-specific rare variants in upstream regions of CYP26A1, CRABP1, and ALDH1A2 ( Figure 1D -F and Table 2 ). Cyp26a1−/− mouse embryos exhibit exencephaly and caudal spina bifida (Abu-Abed et al.,
2001
). The upstream region of Cyp26a1 is highly conserved and has DR5 RARE elements which are bound by RAR receptors to regulate transcription (Loudig et al., 2000) . Similarly, in the upstream region of CRABP1 there is a DR2 RARE element ( Figure 1E ) and NTDs in humans have been associated with ectopic occupation of CRABP1 promoters by RXR receptors and histone alterations .
Aldh1a2 null mouse embryos exhibit craniorachischisis (Niederreither et al., 1999) . In view of our findings that NTD-specific rare variants are located 130-1,664 bp upstream of the RARE for these three genes, we postulate that these allelic variants impact the binding of RA receptors and/or the transcriptional regulation of these key genes. Furthermore, transcription factor binding predictions suggest the possible impact of NTD-specific variants on the expression of these genes ( Figure 1D-F) .
In summary, our data provide a dataset of novel rare variants in retinoid-related genes that are genetically correlated with NTD. Our experimental results emphasize the loss-of-function characteristics of these rare mutations encoding for the RA degradation enzyme CYP26B1. Our findings together with genetic association studies by others (Deak et al., 2005; Rat et al., 2006; Tran et al., 2011) highlight this functional pathway in the genetic contribution of rare mutations to human NTDs.
